ALNY Plunges 25% as Amvuttra Patient Start Slowdown Casts Doubt on Growth Trajectory

What happened

Alnylam shares fell 25% on October 30, 2026, despite Q3 earnings beating consensus, as investor focus shifted to slower-than-expected Amvuttra patient starts, the key driver of future revenue. The market reaction underscores the sensitivity to new-patient additions in ATTR-CM, which is the primary growth engine, and confirms the master report's concern that even a modest slowdown can trigger sharp drawdowns. The earnings beat was likely driven by in-line or slightly better financial metrics, but the forward-looking demand indicators (patient starts) missed expectations, implying that FY2026 guidance may be at risk, particularly the $4.9B–$5.3B combined net product revenue target. Competition from BridgeBio's Attruby and payer restrictions continue to pressure new-start share, and this print suggests those pressures are materializing. The dramatic decline likely brings the stock near the master report's attractive entry of $300, but the bear case probability has increased to reflect weaker demand conversion.

Implication

The 25% drop alters the risk-reward, moving the stock toward the previously identified attractive entry of $300, but the underlying thesis has weakened because slower patient starts suggest the growth trajectory may be lower than modeled. The base case of $360 implied value becomes less certain, and the bear case of $260 gains probability, especially if competitive pressures and payer restrictions continue to dampen new starts. The next few quarters will be critical: management must demonstrate that the slowdown is temporary or that other levers (e.g., ONPATTRO switches, international growth) can offset. Until then, waiting for evidence of patient start recovery or a further price decline to the bear-case value provides a better entry. Investors should monitor quarterly patient start metrics, competitive prescription data from BridgeBio, and any updates to FY2026 guidance, as these will determine whether the stock is a bargain or a value trap.

Thesis delta

The thesis shifts from WAIT to a conditional BUY on weakness, with conviction reduced from 3.5 to 3.0 due to increased execution risk. The slower Amvuttra patient starts directly challenge the base-case revenue trajectory, raising bear-case probability from 30% to 40% and lowering base-case implied value from $360 to $330. However, the sharp decline improves the entry price, making the stock more attractive if management can stabilize starts within the next two quarters.